<DOC>
	<DOC>NCT00267319</DOC>
	<brief_summary>- The study primarily investigates the effect of copaxone on fatigue during treatment, compared to baseline in patients with relapsing-remitting multiple sclerosis. - Secondary outcome measures are:disability, relapse rate, quality of life and depression.</brief_summary>
	<brief_title>FOCUS Fatigue Outcome in Copaxone USers</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>relapsingremitting Multiple Sclerosis (MS), at least 2 relapses in previous 2 years prior to copaxone or interferon beta treatment, ambulant patients i.e disability score EDSS MAX 5,5, clinically stable MS relapse free and steroid free at least 30 days prior to start copaxone treatment hypersensitivity to glatiramer acetate or mannitol, pregnancy, fertile female not willing to use effective contraception, previous treatment with copaxone The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>